Last reviewed · How we verify
Infection by Strongyloides — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Stromectol | ivermectin | Merck & Co. | Antiparasitic [EPC] | Adenosine receptor A3, Multidrug resistance protein 1, Neuronal acetylcholine receptor subunit alpha-7 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
- — Stromectol · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Infection by Strongyloides
- Merck & Co. · 1 drug in Infection by Strongyloides
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Infection by Strongyloides:
- Infection by Strongyloides treatment updates — RSS
- Infection by Strongyloides treatment updates — Atom
- Infection by Strongyloides treatment updates — JSON
Cite this brief
Drug Landscape (2026). Infection by Strongyloides — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-by-strongyloides. Accessed 2026-06-10.
Related
- Infection by Strongyloides full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing